On the 12th, Cue Biopharma, LG Chem’s partner in developing a cancer immunotherapy, announced it had won FDA approval to initiate Phase 1 clinical trials for ‘CUE-102 .’

LG Chem has exclusive rights to develop and market the candidate in 11 Asian countries including Korea, China, and Japan.

With the trial approval, Cue Biopharma will assess CUE-102’s safety, tolerability pharmacokinetics, pharmacodynamics, and preliminary efficacy in treating Wilms' Tumor 1 (WT1)-positive recurrent/metastatic cancers, with an initial focus on gastric, pancreatic, ovarian and colon cancers.

CUE-102 is a cancer immunotherapy that selectively engages and modulates targeted T cells that re